DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 96th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.702
5 - Year: 3.298

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

Author(s): Walter Becker, Ulf Soppa and Francisco J. Tejedor

Affiliation: (Francisco J. Tejedor) Instituto de Neurociencias CSIC-UMH, Universidad Miguel Hernandez-Campus de San Juan, 03550 San Juan (Alicante), Spain.

Abstract

Down syndrome (DS), the most common genetic cause of intellectual disability, is caused by the trisomy of chromosome 21. MNB/DYRK1A (Minibrain/dual specificity tyrosine phosphorylation-regulated kinase 1A) has possibly been the most extensively studied chromosome 21 gene during the last decade due to the remarkable correlation of its functions in the brain with important DS neuropathologies, such as neuronal deficits, dendrite atrophy, spine dysgenesis, precocious Alzheimer’s-like neurodegeneration, and cognitive deficits. MNB/DYRK1A has become an attractive drug target because increasing evidence suggests that its overexpression may induce DS-like neurobiological alterations, and several small-molecule inhibitors of its protein kinase activity are available. Here, we summarize the functional complexity of MNB/DYRK1A from a DS-research perspective, paying particular attention to the capacity of different MNB/DYRK1A inhibitors to reverse the neurobiological alterations caused by the increased activity of MNB/DYRK1A in experimental models. Finally, we discuss the advantages and drawbacks of possible MNB/DYRK1A-based therapeutic strategies that result from the functional, molecular, and pharmacological complexity of MNB/DYRK1A.

Keywords: Down syndrome, minibrain, neuropathologies, cognitive deficit, trisomy 21, harmine, epigallocatechin-gallate.

Download Free Rights and Permissions

  
  



Article Details

Volume: 13
Issue Number: 1
First Page: 26
Last Page: 33
Page Count: 8
DOI: 10.2174/18715273113126660186
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science